GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
Highlights Broad National Support for Domestic Vaccine Resilience and Role of MVA Platform in Public Health Preparedness
ATLANTA, GA - May 29, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, voiced strong support for the newly announced bipartisan initiative by U.S. Senators Joni Ernst (R-IA) and Lisa Blunt Rochester (D-DE) to onshore the manufacturing of critical pharmaceutical supplies. The Critical Infrastructure Manufacturing Feasibility Act seeks to reduce reliance on foreign sources for key medical products - directly aligning with GeoVax's mission to rebuild U.S.-based vaccine manufacturing and strengthen national preparedness.
'We are seeing a unified, national groundswell - from Congress, the White House, HHS, FDA, BARDA, and commissions like NSCEB - calling for the onshoring of America's vaccine manufacturing base,' said David Dodd, Chairman and CEO of GeoVax. 'GeoVax is purpose-built to answer that call, with a clinically validated MVA platform, a domestic manufacturing strategy, and a focus on pandemic responsiveness and protection of the immunocompromised.'
Rebuilding U.S. Biomanufacturing Through Coordinated Federal Action
The Senate initiative complements a cascade of government actions to bring the manufacturing of essential medical countermeasures - including vaccines - back to U.S. soil including:
These actions reflect growing bipartisan recognition that national health security depends on resilient, scalable domestic vaccine capacity.
MVA Technology: Protecting the Immunocompromised with Durable, Multi-Antigen Vaccines
GeoVax's MVA platform supports a pipeline of multi-antigen vaccines, including GEO-CM04S1 (COVID-19), primarily targeted to address the current unmet needs inducing broad T-cell and antibody responses among immunocompromised individuals, overcoming the limitations of single-antigen vaccines.
GeoVax's MVA vaccines align with FDA and HHS goals to advance diversified, multi-antigenic strategies that provide broader, longer-lasting protection across high-risk groups.
Enabling U.S. Biomanufacturing Through Equip-A and BARDA RRPV: A Roadmap to Rapid, U.S.-Based Vaccine Production
GeoVax's progressing advanced MVA manufacturing process is anticipated to eliminate the need for pathogen-free eggs and leverage a continuous avian cell line system, directly supporting the objectives of the federal government's EQUIP-A-Pharma initiative. This HHS-ASPR-DARPA program aims to create agile, point-of-care pharmaceutical production capabilities using modular, AI-driven platforms.
Additionally, GeoVax's proposal - 'Innovation in Clinical Manufacturing of MVA-Vectored COVID-19 Vaccines' - was selected by BARDA's Rapid Response Partnership Vehicle (RRPV), pending funding availability. The program is designed to accelerate the scale-up of advanced U.S.-based MVA vaccine manufacturing. The proposal is designed to:
If funded, this effort is expected to create a scalable, resilient domestic manufacturing platform essential for the rapid deployment of MVA-based vaccines like GEO-CM04S1 (COVID-19) and GEO-MVA (Mpox/smallpox).
Platform Alignment with National Priorities
GeoVax's MVA-based vaccines embody the shift in U.S. public health strategy away from single-antigen platforms and toward multi-antigen, durable, and safe alternatives. These vaccines are specifically engineered to meet the needs of high-risk populations - including the 40+ million immunocompromised Americans who may not respond effectively to mRNA and other vaccines that focus primarily on inducing antibody immunity.
GeoVax's U.S.-controlled MVA platform addresses key government objectives:
Call for Continued Bipartisan Momentum
'With renewed bipartisan focus on U.S. medical independence, there is no better time to invest in American-homegrown vaccine innovation,' added Dodd. 'We urge lawmakers and federal agencies to continue supporting domestic capacity, biodefense readiness, and equitable access to advanced medical countermeasures to protect both our national security and our most vulnerable populations.'
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
[email protected]
678-384-7220
Investor Relations Contact:
[email protected]
212-698-8696
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
35 minutes ago
- Boston Globe
Wall Street is betting Iran Will ‘aim lower' — for now
The most immediate concern is that Iran will disrupt the flow of Persian Gulf oil and natural gas through Advertisement About a fifth of the world's oil and liquefied natural gas passes through the narrow strait between Iran and Oman that links the gulf to the Arabian Sea. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Most of those shipments go to Asia, but the United States would still see rapidly rising energy prices if Iran succeeded in blocking Hormuz. That could further slow an economy already battling headwinds from tariffs, cooling consumer spending, and cautious business sentiment. 'The risks of a financial crisis are rising,' Diane Swonk, chief US economist at KPMG, But the economy has proven remarkably resilient, shaking off mass layoffs during COVID, the red-hot inflation that followed, and the shock of Trump's aggressive tariffs. Investors have hung on throughout. Advertisement US stocks opened with modest gains on Monday. After an initial rise, oil futures were down about 2.5 percent on the New York Mercantile Exchange. 'It will take some time for this conflict to settle, but the market will view the worst is now in the rear-view mirror,' Wedbush analyst Dan Ives said Sunday on X. 'Expect stocks up.' Iran has three basic options for responding to the United States and Israel, James Stavridis, dean emeritus of the Fletcher School of Law and Diplomacy at Tufts University, wrote Monday in a Bloomberg op-ed column. According to Stavridis, Iran could: Abandon its nuclear ambitions and return to talks — an outcome, he said, that's highly unlikely given the regime's pride and instability. Retaliate with limited, face-saving strikes that avoid major US casualties. Hit back hard by trying to close the Strait of Hormuz, assassinate American targets in the Gulf, and launch cyberattacks to spike oil prices and sow unrest in the West. 'Of the three options, I'd say that Iran's leaders want to seize number three and go big. Yet they also recognize the high risk of such an approach and will probably aim lower: asymmetric attacks and targeted operations against US interests and citizens.' Stavridis said. Investors are betting on the 'aim lower' response — for now. The showdown with Iran complicates an already uncertain US economic outlook. The inflation news has been good after a difficult start to the year. With inflation nearing the Federal Reserve's 2 percent target, the central bank would normally be preparing to cut interest rates. But Trump's tariff war, which threatens to push prices higher, has put the central bank on hold. The Fed voted on Wednesday Advertisement The Fed's cautious stance makes sense because the economy is in good shape and the inflationary effects of Trump's tariffs remain uncertain, Susan M. Collins, president of the Boston Fed, 'I don't see an urgency to adjust rates,' said Collins, one of 12 voting members of the Fed's rate-setting committee this year. 'We do not have that sustained price stability that I'm looking for.' That stability won't be possible without resolutions to two quite different standoffs: the real Mideast war and Trump's tariff war. Larry Edelman can be reached at
Yahoo
38 minutes ago
- Yahoo
MakeMyTrip Announces Closing of Offering of US$1.25 billion 0.00% Convertible Senior Notes Due 2030 and Full Exercise of Option to Purchase Additional Notes
NEW YORK & GURUGRAM, India, June 23, 2025--(BUSINESS WIRE)--MakeMyTrip Ltd (NASDAQ: MMYT, the "Company" or "MakeMyTrip"), today announced the closing of its previously announced offering of US$1.25 billion in aggregate principal amount of 0.00% convertible senior notes due 2030 (the "Notes"), and the exercise in full by the initial purchasers of their option to purchase an additional US$187.5 million in aggregate principal amount of the Notes (collectively, the "Notes Offering"). The Notes were offered in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company also announced today by a separate press release the closing of a registered public offering of 16,000,000 ordinary shares (the "Primary Equity Offering") at US$90 per ordinary share. The underwriters exercised in full their option to purchase 2,400,000 additional ordinary shares. MakeMyTrip received net proceeds from the Notes Offering of approximately US$1.41 billion, after deducting the initial purchasers' discounts and estimated offering expenses payable by the Company. The Company plans to use all of the net proceeds from the Notes Offering and the Primary Equity Offering to repurchase a portion of the Class B ordinary shares of the Company from Group Limited. Terms of the Notes The Notes are senior unsecured obligations of the Company. The Notes will mature on July 1, 2030 unless redeemed, repurchased or converted prior to such date. The Notes will be convertible into ordinary shares of the Company, at the option of the holders, in integral multiples of US$1,000 principal amount, at any time prior to the close of business on the second business day preceding the maturity date. The initial conversion rate of the Notes is 8.2305 ordinary shares per US$1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately US$121.50 per ordinary share and represents a conversion premium of approximately 35% above the public offering price of the ordinary shares, which was US$90 per ordinary share). The conversion rate of the Notes is subject to adjustment upon the occurrence of certain events. On or after July 10, 2028, MakeMyTrip may redeem for cash all or part of the Notes, at its option (such redemption, an "Optional Redemption"), if (x) the Notes are "freely tradable" (as defined in the indenture for the Notes) and all accrued and unpaid special interest, if any, has been paid in full, as of the date the Company sends the notice of redemption and (y) the last reported sale price of MakeMyTrip's ordinary shares has been at least 130% of the conversion price then in effect on (i) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately prior to the date MakeMyTrip provides notice of redemption and (ii) the trading day immediately preceding the date MakeMyTrip sends such notice. MakeMyTrip may also redeem for cash all but not part of the Notes at any time if less than 10% of the aggregate principal amount of Notes issued remains outstanding at such time ("Cleanup Redemption"). In addition, MakeMyTrip may redeem all but not part of the Notes in the event of certain changes in the tax laws ("Tax Redemption"). The redemption price in the case of a Tax Redemption, an Optional Redemption or a Cleanup Redemption will equal 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the related Redemption Date. Holders of the Notes will have the right, at their option, to require the Company to repurchase for cash all or part of their Notes, on July 3, 2028 at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid special interest, if any. In addition, subject to certain conditions and a limited exception, holders of the Notes will have the right to require the Company to repurchase all or part of their Notes upon occurrence of certain events that constitute a fundamental change. In connection with certain corporate events or if the Company issues a notice of Optional Redemption, Cleanup Redemption or Tax Redemption, it will, under certain circumstances, increase the conversion rate for holders who elect to convert their Notes in connection with such corporate event or such Optional Redemption, Cleanup Redemption or Tax Redemption. Other Matters Nothing contained herein shall constitute an offer to sell or the solicitation of an offer to buy any securities, including the Notes or the ordinary shares, nor shall there be any offer or sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. The Primary Equity Offering was made only by means of a separate prospectus supplement and accompanying prospectus pursuant to an effective registration statement filed with the U.S. Securities and Exchange Commission. The Notes and the ordinary shares deliverable upon conversion thereof have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws and are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. Forward-Looking Statements This document contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this document, including but not limited to, statements about MakeMyTrip's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of MakeMyTrip, and growth opportunities, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including "anticipate," "expect," "suggest," "plan," "believe," "intend," "estimate," "target," "project," "should," "could," "would," "may," "will," "forecast" or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of MakeMyTrip, which involve inherent risks and uncertainties, and therefore should not be relied upon as being necessarily indicative of future results. A number of factors, including macro-economic, industry, business, regulatory and other risks, could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: MakeMyTrip's ability to grow at the desired rate or scale and its ability to manage its growth; its ability to further develop its business, including new products and services; its ability to attract and retain partners and consumers; its ability to compete effectively in the intensely competitive and constantly changing market; its ability to continue to raise sufficient capital; its ability to reduce net losses and the use of partner and consumer incentives, and to achieve profitability; potential impact of the complex legal and regulatory environment on its business; its ability to protect and maintain its brand and reputation; general economic, social, and political conditions, currency exchange fluctuations and inflation; expected growth of markets in which MakeMyTrip operates or may operate; and its ability to defend any legal or governmental proceedings instituted against it. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described under "Item 3. Key Information – D. Risk Factors" and in other sections of MakeMyTrip's annual report on Form 20-F for the fiscal year ended March 31, 2025, as well as in other documents filed by MakeMyTrip from time to time with the U.S. Securities and Exchange Commission. All information provided in this release is provided as of the date of issuance of this release, and MakeMyTrip does not undertake any obligation to update any forward-looking statement, except as required under applicable law. About MakeMyTrip Limited We own and operate well-recognized online travel brands, including MakeMyTrip, Goibibo and redBus. Through our primary websites, and mobile platforms, travelers can research, plan and book a wide range of travel services and products in India and overseas. Our services and products include air ticketing, hotel and alternative accommodations bookings, holiday planning and packaging, bus ticketing, rail ticketing, car hire and ancillary travel requirements such as facilitating access to third-party travel insurance, forex services, and visa processing. We provide our customers with access to all major domestic full-service and low-cost airlines operating in India and all major airlines operating to and from India, a comprehensive set of domestic accommodation properties in India and a wide selection of properties outside of India, Indian Railways, and all major Indian bus operators. View source version on Contacts For more details, please contact: Mohit KabraGroup Chief Financial OfficerMakeMyTrip Limitedgroupcfo@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Hims & Hers stock plummets after Novo Nordisk ends Wegovy direct sales deal
Hims & Hers (HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk (NVO) announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims' telehealth platform. Novo Nordisk said that Hims & Hers was breaking the law by continuing to sell copycat semaglutide, the key ingredient in Wegovy, alongside Novo's branded drugs. "Hims & Hers ... has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization,'" Novo said in a statement Monday. The duo announced a collaboration last month that would allow patients to directly purchase Wegovy through Hims' telehealth platform. The agreement followed a growing trend among pharma companies, including Novo's competitor Eli Lilly (LLY) to fill the access gap after copycat, or compounded, GLP-1s were forced off the market. Compounded drugs were available when Lilly and Novo struggled to produce enough of their GLP-1s to meet the unexpected and unprecedented demand spike in the weight-loss market. The Food and Drug Administration (FDA) allows for copycats to be sold when a drug is in short supply without undergoing the same trial requirements as the branded drugs. Since the shortage has ended for both companies' drugs, some compounding pharmacies have continued to make copycats — mostly for Novo's semaglutide. They intend to continue and are allowed to do so due to a loophole that allows patients to have access to "personalized" medicine if they need adjustments to a branded product for reasons like tolerability or allergies. Lilly is also faced with how to manage some telehealth platforms that continue to offer compounded products, including Novo Nordisk's, which Lilly included in its concerns. Hims & Hers did not immediately respond to a request for comment. In addition to the latest ding to the company's stock, investors are expecting Hims & Hers to grow at a slower clip than in the recent past. Hims has been riding the highs (and sometimes volatile swings) in GLP-1 news, especially as it relates to the availability of the copycat drugs. But it is also showing weakness in overall subscriptions to its telehealth platform, according to Bank of America analyst Allen Lutz. Revenue growth year over year has slowed sharply from roughly 45% in the third quarter of 2024 to 29% in the first quarter of this year. In addition, the Federal Trade Commission (FTC) will implement a new rule in July making it easier for customers to cancel subscriptions with one click, which "could impact HIMS churn by simplifying subscription cancellations," Lutz said. Meanwhile, pressure from Congress and the federal government to end direct-to-consumer marketing for pharmaceutical sales could impact Hims, which faced backlash after it advertised compounded GLP-1s during the Super Bowl in February. But there is one potential bright spot, according to Lutz. Hormone replacement therapy (HRT), a potentially $3 billion to $10 billion market, could add $4 million to $12 million for Hims in 2025. "HIMS has a strong history of scaling new categories quickly and hormone replacement therapy (HRT) is the next opportunity," Lutz wrote. "HIMS' DTC [direct-to-consumer] offering is likely to expand the current addressable market over time given strong brand recognition." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Sign in to access your portfolio
